Canagliflozin Alleviates Progestin Resistance by Suppressing RARβ/CRABP2 Signaling in THRB Knockout Endometrial Cancer Cells
April 2025
in “
Frontiers in Pharmacology
”
Studysummary This study found that targeting RARβ and RXRA with CANA, in combination with MPA, could help overcome progestin resistance by restoring BAX levels and downregulating CRABP2, suggesting a novel strategy for improving clinical efficacy in this context.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on frontiersin.org →